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Riassunto 
In una paziente affetta da iperaldosteronismo primario abbiamo identificato la presenza 
di un feocromocitoma non secernente catecolamine. L’analisi del transcrittoma nel 
feocromocitoma ha rivelato un’elevata espressione di Urotensina II (UII). 
L’UII è un peptide ciclico di 11 aminoacidi, identificato inizialmente nel sistema 
neurosecretorio dei pesci teleostei e successivamente nell’uomo, che oggi è ritenuto un 
potentissimo vasocostrittore coinvolto nella fisiologia e nella fisiopatologia del sistema 
cardiovascolare i cui meccanismi di azione sono tuttora largamente sconosciuti.  Molti 
studi su diversi modelli animali, sia in-vitro che in-vivo, hanno documentato che l’UII 
può indurre ipertrofia cardiaca, aumento della matrice extracellulare e riduzione della 
contrattilità miocardica, suggerendo una sua possibile implicazione  nel rimodellamento 
cardiaco post-ischemico o nell’insufficienza cardiaca. Nonostante i suoi effetti sul cuore 
e sull’omeostasi pressoria siano tuttora controversi si è generato un notevole interesse 
nell’identificazione del ruolo fisiologico dell’UII e dei suoi meccanismi d’azione. 
Abbiamo studiato l’espressione dell’UII e del suo recettore nel contesto delle ghiandole 
surrenaliche e in diversi tumori surrenalici constatando un andamento pressochè 
opposto circa l’espressione di UII e del suo recettore tra feocromocitoma ed adenoma 
secernente aldosterone:  nel feocromocitoma si è documentato un più alto contenuto di 
di UII rispetto all’adenoma secernente aldosterone che, viceversa,  ha mostrato una 
maggiore espressione del recettore, suggerendo una down-regulation recettoriale 
secondaria alla produzione di UII. Queste evidenze suggeriscono un ruolo importante 
dell’UII nelle interazioni paracrine tra midollare e corticale surrenalica e nella 
fisiopatologia del pheocromocitoma e dell’adenoma secernente aldosterone, dando 
peraltro una spiegazione meccanicistica per quei feocromocitomi che si presentano 
clinicamente con iperaldosteronismo. 
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Abbiamo inoltre testato in vivo l’effetto dell’UII sulla pressione arteriosa mediante la 
sua infusione cronica nel ratto documentando un andamento pressorio molto simile a 
quello che si ottiene nell’infusione cronica di aldosterone e caratterizzato da un iniziale 
effetto ipertensivo seguito da un adattamento pressorio verso i valori di partenza. 
Questo supporta ulteriormente l’ipotesi di stretta interazione tra UII e sistema renina-
angiotensina-aldosterone o addirittura di un’azione dell’UII  mediata dalla produzione 
di aldosterone. A questo proposito, partendo dal presupposto che il peculiare andamento 
pressorio negli stati di iperaldosteronismo è pesantemente influenzato dagli adattamenti 
di volume che si verificano grazie al fenomeno renale di “escape” abbiamo voluto 
verificare se vi fossero cambiamenti significativi nell’andamento pressorio durante 
l’infusione cronica di UII e la concomitante soppressione del meccanismo di escape. I 
risultati sono stati sorprendenti visto che per la prima volta si è documentato in vivo un 
effetto ipertensivo, non solo transitorio ma continuativo, dell’UII. 
Le evidenze ottenute, sia per quel che riguarda gli effetti dell’UII sulla pressione 
arteriosa che sullo sviluppo dei tumori surrenalici, sicuramente consentono di fare un 
passo in avanti circa l’identificazione del  meccanismo d’azione  a sostegno dell’ipotesi 
che l’UII possa agire come mediatore tra midollare e corticale surrenalica o mediante la 
produzione stessa di aldosterone. Gli studi in cui prevediamo di utilizzare ratti 
transgenici per l’espressione di UII nella midollare surrenalica potranno  contribuire a 
confermare o confutare la nostra ipotesi.  
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Abstract 
 
In a patient affected by primary aldosteronism we have identified the presence of a 
pheochromocytoma not secreting catecholamines. The analysis of the transcriptome in 
the pheochromocytoma revealed a high expression of Urotensin II (UII). 
UII is a somatostatin-like cyclic 11-aminoacid vasoconstrictor peptide, first identified in 
the teleost fish caudal-neuro-secretory system and then in humans, that has been 
demonstrated to be a potent vasoactive peptide involved in the physiology and 
pathophysiology of the cardiovascular system through mechanisms still largely 
unknown. Its action is now the subject of intensive studies on the effects it produces in 
different animal models and in different vascular beds. The direct effects on the 
myocardium such as ventricular hypertrophy, increased extracellular matrix and 
reduction of myocardial contractility suggest a role of UII in cardiac remodelling after 
myocardial infarction and heart failure. Even if the effects on cardiovascular system are 
still controversial UII has attracted considerable scientific interest aimed to investigate  
on its pathophysiology and on  its the mechanism of action.  
We investigated among the expression of UII and its receptor in human adrenal glands 
and in different adrenal tumors. The opposite trend of expression of  UII receptor 
obtained between aldosterone-producing adenoma and pheocromocitoma, along with 
the differences of genes implicated in UII signaling, supported a role of UII in the 
paracrine interactions between the adrenal medulla and cortex. Being relevant for the 
regulation of adrenal gland function and for the pathophysiology of pheocromocitoma 
and aldosterone-producing adenomas, these interactions might provide a mechanistic 
explanation for the pheocromocitomas that presented clinically as aldosteronism. 
We tested the “in vivo” effects of UII on blood pressure in rats, showing a delayed 
transient hypertensive effect  that  resembles the pressure trend in chronic infusion of 
10 
 
aldosterone. Thus further supporting the hypothesis of a close interaction between  UII 
and the renin-angiotensin-aldosterone system or even that UII acts through production 
of aldosterone as well as assess its hypertensive activity, its effect of cardiac 
hypertrophy and fibrosis and its role in regulating the growth of adrenocortical cells in 
rats.  Considering that the mechanisms involved in the so called “escape phenomenon” 
seem responsible of the peculiar blood pressure trend in hyperaldosteronism we tested 
the blood pressure modifications  in chronic infusion of UII counteracting the “escape 
phenomenon” through unilateral nephrectomy, high salt diet and concomitant infusion 
of spironolactone.  The results obtained were promising: for the first time was shown an 
in-vivo not transient but continuous hypertensive effect of UII. 
The evidences obtained in blood pressure modification during chronic infusion of UII 
combined with the ones regarding UII and development of cortical tumors, has taken a 
step forward in identifying the mechanism of action of UII supporting the hypothesis of 
a possible close communication between medulla and adrenal cortex and a possible 
action of UII mediated by aldosterone. Additional investigations on the transgenic rat 
overexpressing UII in adrenal medulla will certainly contribute to verify our hypothesis. 
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1. Urotensin II 
Urotensin II (UII) is a somatostatin-like 11-aminoacid (ETPDCFWKTCV) 
vasoconstrictor peptide that was initially isolated from the urophysis of the goby fish 
(Gillichthys mirabilis)
1
 and subsequently from the white suckerfish and the carp. 
Although there were variations in the amino acid sequence near the N-terminus, in both 
species the UII molecule retained the COOH-terminal cyclic sequence: -Cys6-Phe7-
Trp8-Lys9-Tyr10-Cys11 (Figure 1). It is this sequence, likewise for somatostatin,  that 
is thought to confer biological activity to the peptide.
2
 The in vitro demonstration of the 
vasoactive effects of fish UII in rats and in human vessels
3,4
 led to identify a 
mammalian homolog. As the fish UII activated the orphan G protein coupled receptor 
GPR14, a human GenBank search was performed using the fish UII sequence. This led 
to the discovery of a human-expressed sequence tag with 25% identity to the fish 
sequence yielding a 688-base pair cDNA from which the human UII propeptide amino 
acid sequence was deduced.
5
  Recent evidences support the notion that UII belongs to 
the same gene superfamily of   somatostatin. The remarkable conservation of 
somatostatin-like peptides among the species underscores the vital role of UII as a basic 
physiological mediator.
6
 
After its discovery and isolation UII was revealed to be a very potent vasoconstrictor 
sharing  many functional similarities with other vasoactive peptides. UII elicits strong 
vascular smooth muscle cell (VSMC)-dependent vasoconstriction and weak 
endothelium-dependent vasodilation as endothelin 1 (ET-1). Like ET-1 and 
adrenomedullin, the circulating concentrations of UII in humans are found to be very 
low (picomolar range), which suggests that UII acts in an autocrine and paracrine 
fashion.
7
 This theory is supported also by the fact that both the body distribution and  
the plasma concentration of UII and its receptor (UT-R) are very similar to those of 
14 
 
other known powerful autocrine-paracrine endothelial-derived vasoconstrictors.
8
 
Moreover the UT-R, like the ET-1 and angiotensin II receptors, is coupled to a Gq11 
subtype of heterotrimeric G proteins. Like angiotensin II, UII is thought to elicit RhoA 
membrane translocation and activation via receptor-Gq11 coupling.
8
 
Although the sources of UII production in the body remain to be fully determinated, 
arteriovenous gradients have been identified across the heart, liver, kidney, pancreas  
and adrenals indicating that these organs may be primary sources for UII.
9
  Moreover 
altered plasma concentrations of UII have been detected in several pathological 
conditions, such as heart failure, essential hypertension, renal disease, diabetes, and 
liver cirrhosis
10 
suggesting the potential usefulness of UII as a biomarker. This has 
stimulated a great deal of research on its possible implications in the pathophysiology of 
many cardiovascular diseases.  
 
 
1.1 UII receptor 
The UII receptor (UT-R) was initially discovered in rat using PCR and genomic DNA 
library screening; an orphan G protein-coupled receptor was discovered and termed 
GPR14. GPR14 showed a 27% overall sequence homology with the somatostatin 
receptor SSTR4. Rat GPR14 was used to probe the human genomic library which 
allowed the detection of a human 389 amino acid GPCR with 75% identity to rat 
GPR14. Subsequently, the functional role of the orphan GPR14 was discovered proving 
the human GPR14 receptor to be highly selective for the fish and human UII. This led to 
the identification of GPR14 as the UT-R.
11,12
 
The studies carried out on the interactions between UII and UT-R provided evidence 
that the COOH-terminal region is largely responsible for the biological activity of UII. 
15 
 
Moreover investigations on the structure and function of UT receptor  suggest that  
transmembrane domains IV, VI, and VII are involved in the formation of the ligand-
receptor binding pocket.
13-15 
 
 
Figure 1. Urotensin II amino-acid configuration (A) and its G protein 
copulated receptor (B) 
 
 
This receptor has been identified in varying amounts in cardiac myocytes, VSMCs, 
endothelial cells, spinal cord, central nervous system, and kidneys. On the other hand, 
UII has been detected by immunohistochemistry in blood vessels of the heart, pancreas, 
kidney, placenta, thyroid, adrenal gland, and umbilical cord, as well as in human 
epithelial cells of the kidneys. Both ligand and receptor seem to be ubiquitously 
expressed in human tissues though lymphocytes and macrophages, respectively, are the 
largest producers of UII and UT-R in sites of atherosclerotic lesions. 
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1.2 Vasoactive activity of UII 
In vitro studies showed that UII elicited contractile effects on most smooth muscle of 
fishes and in mammalian tissue
16
. These in vitro demonstrations proved that the 
contractile potency of UII (-log[EC50] of 9.09) was greater than that of ET-1 (-
log[EC50] of 7.9), noradrenaline (-log[EC50] of 7.58), and serotonin (-log[EC50] of 
6.27), making UII the most potent human vasoconstrictor identified to date.
17,18
  
Many studies have examined the effects of UII on the vasculature and have reported 
large differences in responses to UII among species, different vascular beds and even 
within the same vascular bed of the same species. An example of this is the isolated rat 
aorta, where potent vasoconstriction is observed in the thoracic segments with lower 
effect in the abdominal portion (estimated approximately about 27% of that expressed 
on the thoracic segments). This differential responsiveness may be due to differences in 
the expression level of UT-Rs, or to the ability of the receptor to couple to its signaling 
pathway.
16
 The action of UII was found to be independent of endothelial cells and to 
work via mobilization of intracellular calcium as well as through stimulation of 
extracellular calcium influx (Ca
2+
 release via PLC/dependent IP3 and calmodulin-
dependent myosin light-chain kinase pathways).
17
 Contrary, subsequent studies showed 
a possible mediation of endothelial cells (by NO production) determining relaxation of 
rat aortic tissue (precontracted with noradrenaline) in presence of lower concentration of 
UII with the maintenance of  the contractile effect at higher concentration.
18
 
Further experiments where performed also with human UII showing an extremely 
powerful contractile effect (greater than ET-1) on isolated rat aorta,
5
 completely 
independent by the endothelial cells and without evidence of relaxation of precontracted 
aorta.   
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1.2 UII and cardiovascular system 
Regarding cardiac tissue,  recently the presence of UII and its receptor in both myocytes 
and cardiac fibroblasts has been demonstrated; moreover has been suggested a possible 
role of UII in cardiac fibrosis.
19
 Furthermore, in a rat model of heart failure following 
myocardial infarction, UII and UT-R expression were increased in both infarct and non-
infarct regions of the left ventricle (LV) compared with sham-operated controls,
20
 
suggesting an important role for UII in myocardial ischemia. Additionally, in vitro 
stimulation of rat neonatal cardiac fibroblasts with UII has been shown to result in 
increased collagen synthesis and increased expression of the extracellular matrix 
proteins α1(I)- procollagen, α1 (III)-procollagen and fibronectin genes similar to, or 
greater than, that produced by the profibrotic stimulus, endothelin. Adenoviral-mediated 
overexpression of the rat UT-R in neonatal fibroblasts results in a two-fold increase in 
collagen synthesis following UII stimulation, suggesting that the up regulation of UT-R 
expression observed during pathophysiological conditions such as myocardial 
infarction, may be responsible for increase in collagen synthesis observed under these 
conditions.
20
 Such pro-fibrotic effects lead to cellular hypertrophy, protein synthesis, 
and expression of natriuretic factors, all induced by UII.
20-22
 
UII stimulation of rat neonatal cardiomyocytes, either transiently transfected with 
recombinant rat UT receptor or infected with adenoviruses expressing the rat UT-R, 
results in a hypertrophic phenotype inducing atrial natriuretic peptide (ANP), myosin 
light chain 2v-CAT and α skeletal actin activity.  In addition, UII increases protein 
synthesis, myocyte size and myofibril organization pathways.
20
   
UII has been shown to have a direct inotropic effects on the myocardium, increasing 
contractility in human right atrial trabeculae in a dose-dependent manner. A small 
increase in contractility was observed at a maximal UII concentration in right 
18 
 
ventricular trabeculae from an explanted heart with idiopathic dilated cardiomyopathy. 
This responsiveness of UII is consistent with the expression of UT-Rs previously 
determined in all four chambers of the heart.
21
  
In heart failure UII plasma concentrations are not only increased but also correlate with 
Big ET-1  and brain natriuretic peptide levels as well as with NYHA functional 
classes
22,23 
further supporting the hypothesis that UII plays a predominant role in the 
pathophysiology of the cardiovascular system.  
 
 
1.4 UII and atherogenesis 
UII has been shown to act as a mitogenic and hypertrophic agent resulting, in part, in 
the enlargement of cells and in the reorganization of sarcomeres. These cellular 
responses result from UT-R-binding which promote tyrosine phosphorylation of 
epidermal growth factor receptor and in turn activate mitogen-activating protein 
kinases, extracellular signal-regulated kinase 1/2 (ERK 1/2), and p38.
24,25
 UII seems 
also to increase cell proliferation in VSMCs by acting synergistically with oxidized 
low-density lipoproteins (LDL), amongst several other mitogens.
24
 UII has also been 
shown to increase expression of NADPH oxidase and plasminogen activator inhibitor-1 
(PAI-1) in VSMCs. These observations, in association with the evidences emerged 
using transgenic and crossbred mouse strains showing that selective induction of UT-R 
expression in mice VSMCs displayed far greater aortic lesions, led to hypothesize a role 
of UII in the progressing of atherosclerosis.
26
  
In addiction  among the inflammatory cell population, lymphocytes appear to be the 
largest producers of UII, whereas monocytes and macrophages appear to express the 
19 
 
UT-R to support that UII is an important mediator in inflammatory processes such as 
atherosclerosis.
27 
 
 
 
1.5 UII, insulin resistance and metabolic syndrome 
UII seems also to have a role in insulin secretion and the pathogenesis of type II 
diabetes mellitus (DMII). Both UII and UT-R are present in the human pancreas and 
seem to directly inhibit beta cell function, thus inhibiting insulin release.
28,29 
In fact, UII 
levels have been reported to be 1.7-fold higher in diabetic patients than in healthy 
controls. However, UII levels did not correlate with fasting blood sugar levels 
demonstrating that hyperglycemia is not responsible for UII increase. It has been 
suggested that elevated UII plasma concentrations in metabolic syndrome may be a 
result of damaged endothelial cells, as is the case in cardiovascular diseases.
30
 The 
metabolic syndrome, which includes DMII, is associated with increased inflammatory 
cytokines and elevated free fatty acids across its spectrum. In fact, UII can up-regulate 
IL-6 which plays a role in atherogenesis and hypertrophy, as well as in insulin 
resistance.
31 
Insulin resistance may further impair vasodilation, as plasma insulin levels 
and blood pressure are correlated in patients with hypertension. Interestingly, several 
single nucleotide polymorphism  identified on the UII gene have been associated with 
insulin resistance and therefore with a susceptibility to DMII. In addition, DMII patients 
with renal dysfunction exhibited plasma and urine UII levels higher than in patients 
with normal function.
30
 These elevated levels are probably due to an increased 
production of UII in renal tubular cells as a result of renal damage. In effect, insulin 
resistance causes increased blood pressure and consequently results in atherosclerosis 
and renal damage. These observations may have important implications in the 
20 
 
understanding of micro and macro-vascular disease, which is a consequence of this 
condition. 
The discovery of  CT-058362, commonly known as palosuran, the most known potent, 
selective, and competitive antagonist of the UT-R,
32-34
 allowed several investigation 
resulting in an increase of knowledge on the possible systemic effects of UII. 
In an experimental study, it has been shown that long term treatment of streptozotocin-
induced diabetic rats with palosuran improved survival, increased insulin, and slowed 
the increase in glycemia, glycosylated hemoglobin, and serum lipids. Furthermore, 
palosuran increased renal blood flow and delayed the development of proteinuria and 
renal damage.
33
 These evidences suggest that UT-R antagonism might be a new 
therapeutic approach for the treatment and/or prevention of diabetic nephropathy. UII is 
also thought to play a role in kidney physiology, as increased plasma UII levels have 
been reported in chronic renal failure patients on hemodialysis as well as in those not 
yet requiring dialysis.
35
 This increase can, however, merely represent impaired 
clearance of UII from the circulation, rather than increased production in these patients.  
Palosuran was shown to be effective  in macroalbuminuric diabetic patients who are 
prone to the development of renal disease with an overall clinically significant reduction 
of 24.3% in the 24-hour urinary albumin excretion rate.
36
 
 
 
 
1.6 UII and blood pressure 
On the basis of available evidence on the vasoconstricting properties of UII it is 
altogether likely that UII can directly or indirectly be involved in the homeostasis of 
blood pressure (BP). Acute systemic effects of UII have been assessed in some in vivo 
animal models with controversial results. Infusion of UII in cynomologus monkey 
21 
 
demonstrated reductions in mean BP together with reduction in carotid blood flow and 
reduced cardiac output as well as increase in LV end-diastolic pressure and total 
peripheral resistance. However the animals thereafter went into a state of cardiovascular 
collapse which was thought to be related to either reduced cardiac function and/or 
impaired coronary perfusion due to intense coronary vasoconstriction.
5
 
Some other studies  reported different effects of UII, resulting in myocardial depression 
and fatal circulatory collapse. UII reduced heart rate, mean blood pressure, and carotid 
and coronary blood flow, but pulmonary pressure was increased
25
. This increase in 
pulmonary pressure was consistent with the in vitro evidences that UII is a potent 
vasoconstrictor of primate pulmonary arteries
37
 and may be important in the 
development of right ventricular (RV) heart failure. Similar hemodynamic effects of UII 
have been noted in anesthetized rats causing systemic vasodepression.
38,39
 
More recent studies assessing the acute effects of UII infusion on hemodynamics and 
cardiac function in rats found that UII dose-dependently decreased mean arterial 
pressure, LV systolic pressure and dP/dt in the first 5 min following administration.
39 
In 
conscious rats UII caused a vasodilation accompanied by an increased heart rate, 
probably due to a direct action of UII as well as baroreceptor reflex activation.    
In the first study investigating the effects of chronic infusion of UII in rats it was shown 
that, although the dose used of 300µmol UII /Kg/h  had no effect on systemic pressures,  
it markedly decreased myocardial contractility (40% increase of left ventricular end 
diastolic pressure)   probably secondary to an increase of  the proportion of collagen 
I:III in the LV.
40
 
In vivo studies on the role of UII in the  homeostasis of BP are nowadays few and their 
results, sometimes conflicting, do not provide reliable information on the BP response 
of the organism exposed to high levels of UII,  leaving many questions unresolved.  In 
fact it would be natural to assume that an endocrine-peptide with such an intense 
22 
 
vasoconstrictor activity has a systemic hypertensive effect contrary to what emerged 
since now. Can UII increase BP? And if so, when and how does it happen? Could be 
possible a transient  hypertensive effect of UII subsequently damped by a series of 
systemic responses of the organism?  
If this exist, probably a continuous and invasive blood pressure monitoring could help 
on identifying all the BP variations since the beginning of a chronic infusion of high 
levels of UII, thus that may have not been identified in in vivo studies already 
conducted. Beside remain completely unknown mechanisms by which the UII may acts 
on BP  homeostasis and the hypothesis that the activity  of UII is closely related with 
some other endocrine system seems to be more and more consistent.  
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2. Is UII involved in secretion of aldosterone? 
The research mark in the field of hypertension especially regarding the renin-
angiotensin-aldosterone system (RAAS) led us to hypothesize a synergistic action 
between UII and RAAS or even by means of the direct stimulation of production of 
other mediators such as aldosterone. 
The concomitant studies we have carried out on adrenal glands in patients affected by 
hyperaldosteronism showed  an increased expression of UII and its receptor in different 
adrenal tumors, suggesting  a role of UII in regulating the growth of adrenocortical 
cells.41  On this basis we hypothesized a role of UII in hyperaldosteronism aimed to 
clarify its mechanism of action. 
 
 
2.1 Notes on primary aldosteronism 
Primary aldosteronism (PA) is an endocrine disorder characterized by an excessive 
production of aldosterone totally or partially independent by the RAAS. The 
inappropriate mineralocorticoid activity resulting determine the suppression of renin, 
salt retention and excessive urinary excretion of potassium. Clinically this corresponds 
to the appearance of arterial hypertension of varying degrees, sometimes resistant to 
medical therapy, and in a certain percentage of cases, of hypokalemia and metabolic 
alkalosis. The cause of PA lies in the excessive secretion of aldosterone by the adrenal 
cortical tissue: different classifications that result can therefore emphasize the neoplastic 
or hyperplastic origin of the disease, or the mono/bilateral nature of the phenomenon. 
For the purpose of choosing the best treatment, however, the classification that is more 
effective and functional is that which distinguishes forms surgically treatable 
(monolateral disease) by forms not surgical treatable (bilateral disease)
42
 (Table 1). 
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Classically, forms recognized as the most representative of the two categories, are 
respectively the aldosterone-producing adenoma (APA) and idiopathic 
hyperaldosteronism (IHA), which corresponds anatomo-pathologically to the bilateral 
adrenal hyperplasia (BAH) that usually occurs with a milder clinical presentation.
43
 
Other subtypes include: 
1) The adrenal cortical carcinoma (APC, aldosterone-producing adrenal 
carcinoma), which generally is distinguished by the adenoma because of the 
bigger size, the ability to produce other steroids over aldosterone (ex. 
androgens), the tendency to local invasiveness and metastasis, the presence of 
areas of necrosis and a high number of mitoses.  
2) The unilateral adrenal hyperplasia (UAH, unilateral adrenal hyperplasia) where 
the aldosterone excess originates from hyperplasia of only one of the two 
adrenal glands and which is correctable by surgical removal of the adrenal 
affected, and the condition known as “MUAN” (unilateral multiple 
adrenocortical micronodules), of which only 5 cases have been reported up to 
day
44,45 
which clinical relevance is considered so high to be sometimes classified 
as independent category.  
3) Familial hyperaldosteronism type I (FH type I) correctable with 
glucocorticoids, also known as GRA (glucocorticoid remediable aldosteronism) 
which is an autosomal dominant genetic disorder characterized by high 
production of aldosterone ACTH-dependent and high levels of hybrid steroids 
(18OHcortisol and 18oxo-cortisol) hypertension and renin suppression.  
In FH type II, in which is observed in the same family the presence of BAH or 
of APA
46
, the transmission seems autosomal dominant although the small 
number of affected cases in the families studied and reported in the literature do 
not allow to  establish it with certainty. The FH type II is also indistinguishable 
25 
 
clinically, biochemically and morphologically from forms of PA apparently 
"sporadic". It is therefore considered that on the basis of such phenotypic 
variability is genetic heterogeneity, with possible involvement of several genes 
active in the regulation of steroidogenesis or cellular proliferation.
47
   
Recently it has been described a case that constitute a new form of PA family 
(FH type III) characterized by severe hypertension, hyperaldosteronism and 
hypokalemia with significant organ damage already in pediatric age, resistant to 
aggressive antihypertensive therapy, with levels of hybrids steroids up to 1000 
times higher than patients with glucocorticoid remediable aldosteronism (GRA), 
paradoxical response to dexamethasone suppression test (increased aldosterone 
and lack of suppression of cortisol) and very marked unilateral adrenal 
hyperplasia.
48
  
 
 
Surgically treatable 
 
- Aldosterone-secreting adenoma (APA) 
- unilateral 
- bilateral 
- Unilateral adrenal hyperplasia (UAH) 
- Unilateral micronodular adrenal hyperplasia (Muan) 
- Ovarian Cancer aldosterone-secreting 
- APA or bilateral hyperplasia (BAH) with concomitant pheochromocytoma 
- Adrenal cortical carcinoma 
 
Not surgically treatable 
 
- Bilateral adrenal hyperplasia (BAH) 
- Unilateral APA and BAH 
- Family hyperaldosteronism type I (FHI), also known as hyperaldosteronism correctable with 
  glucocorticoids (GRA) 
- Hyperaldosteronism familial type II (FHII) 
- Apparent mineralocorticoid excess (AME) 
- Chronic consumption of liquorice 
- Use of carbenoxolone 
 
Table 1. Causes of primary aldosteronysm 
 
(What today really discriminate between the choice of a surgical or a pharmacological 
approach is not in fact the “morphological data” of unilaterality of the lesion, but the 
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“functional data” deriving from the adrenal venous catheterization (AVS, adrenal 
venous sampling). To underscore how this investigation is decisive, the results of the 
study PAPY 
49
 have recently shown that the  proportion of the two PA subtypes, object 
in the past of conflicting assessments, is actually intimately conditioned by the 
availability of the AVS. In centers where this diagnostic test is used, the APA include 
about 2/3 of cases of PA, while in other places the IHA is the subtype more frequent). 
 
Despite the existence of these rare forms, it is clear that by far the most common 
subtypes of PA are APA and BAH. However, this dichotomy between adenoma and 
hyperplasia, apparently simple and solid, in reality sometimes leaves space to 
differentiative challenges because of the lack of well-defined criteria concerning their 
functional and morphologic characterization. The tissue surrounding the adenoma 
usually shows paradoxical hyperplasic changes and contains multiple nodules ranging 
from microscopic to macroscopic measures. Moreover, cases of multinodular adrenal 
hyperplasia with evidence of lateralization of aldosterone secretion are widely 
documented. Therefore, bilateral hyperplasia and aldosterone-producing adenoma could 
be regarded as steps of a common pathological continuum, which could feature a 
gradual transition from hyperplasia to a nodular phase. However the underlying 
biological mechanisms driving this evolution are unknown. Since the multinodularity of 
adrenal glands from PA patients is reminiscent of multinodular goiters and Graves’ 
disease, it can be hypothesized the involvement of immunological phenomena as a 
common pathogenic background. Recent studies from our group provide support to this 
interpretation.
50 
 Overall, even though a conclusive proof for an autoimmune basis of 
PA pathogenesis remains to be given, a strong implication of the immune system in PA 
genesis could be contended. It would seem reasonable to argue that humoral immunity 
could trigger an hyperplastic and eventually tumorous expansion of adrenal cells, and 
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cell-mediated mechanisms could take part in this process by controlling its 
development.  
If in PA are established clinical conditions such as high BP, reduction in plasma levels 
of potassium and angiotensin II, which should break down the values of aldosterone, it’s 
not clear why the levels of aldosterone remain high. It is reasonable to assume that the 
humoral autoimmune phenomena above described could contribute in a small 
percentage of case to the maintenance of aldosterone production. Recently mutations in 
KCNJ5 gene which encodes the inward rectifying K
+
 channel Kir3 have been shown to 
be involved  in the pathogenesis of both FH-III and sporadic APA.
50
  Although the role 
of the wild-type KCNJ5 protein in the regulation of aldosterone biosynthesis remains 
unclear, two recurring mutations in the KCNJ5 gene are commonly found in APA 
tumors. Transcriptome and real-time PCR analyses demonstrate that APA with KCNJ5 
mutations exhibit enhanced CYP11B2 expression and that overexpression of KCNJ5 
mutations in adrenal cells increases aldosterone production by augmenting the 
transcription of CYP11B2 and of its regulatory transcription factors.
52
 Besides these 
findings certainly the overproduction of aldosterone may led to speculate among other 
mechanism such as humoral stimulation by other peptides: the parathyroid hormone 
(PTH) for example stimulates aldosterone secretion and cell proliferation in human 
adrenocortical cells; moreover, in rats hyperaldosteronism has been shown to be 
associated with hyperparathyroidism. Hence, PTH could drive aldosterone excess in 
human primary aldosteronism.
53
  
In this regard may be reasonable to speculate if also UII may contribute to the hyper-
secretion of aldosterone and to the onset of PA. 
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3. Is there any evidence that UII can induce high blood pressure and primary 
aldosteronism in humans? 
Many evidences show that the functional regulation of the adrenal gland involves 
paracrine interactions of numerous peptides
54,55
 and UII and its receptors (UT-Rs)
56-59
 is 
widely expressed in many tissues
56-63
 including the vasculature and the adrenal gland.
66-
66
 The finding of UII and UT-R gene transcripts in aldosterone-producing adenoma 
(APA) and pheochromocytoma (Pheo)
66,67
 suggested the participation of UII in the 
regulation of blood pressure and body fluid homeostasis. Despite the quantitative 
expression of UII and UT-R in APA and Pheo and the biological effects of UII in the 
adrenal gland are unknown, the suspicion of a paracrine effect in the context of the 
gland on the basis of these diseases is increasingly founded. 
In rare cases PA and Pheo are found simultaneously
68-74
.
 
These cases have been the 
object of a great scientific speculation which led to the hypothesis that the PA can 
sometimes be "secondary" to Pheo by stimulation of the zona glomerulosa through 
unknown mediators. 
 
 
3.1 Clinical case 
A lady of 44 year-old was elsewhere diagnosed, about 10 years before with idiopathic 
hyperaldosteronism because of the detection of persisting hypertension and 
hypokalemia. During the follow-up (ultrasound, CT scan and arteriography) a left 
adrenal mass compatible with a left adrenal adenoma was identified. However, the 
adrenal vein sampling (AVS) highlighted an increased aldosterone production by the 
right kidney (Tables 2,3), and for this reason the patient was submitted to right 
adrenalectomy.  
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 Baseline 
(ng/ml) 
Post ACTH  
(ng/ml) 
Cort IVC  259 204 
Cort RAV 286 239 
Cort LAV  704 594 
Aldo IVC  594 457 
Aldo RAV  413 528 
Aldo LAV  825 704 
 
Table 2.  Cortisol and aldosterone levels in selective sampling of  inferior vena cava (IVC), right adrenal 
vein (RAV) and left adrenal vein (LAV) 
 
 
 
 
 
 
 
 Baseline 
(ng/ml) 
Post ACTH  
(ng/ml) 
Cort RAV/IVC 1.1 1.17 
Cort LAV/IVC 2.72 2.91 
Aldo RAV/Cort RAV/Aldo 
LAV/cort LAV 
1.26 1.83 
 
Table 3.  Cortisol and aldosterone levels in selective sampling of  inferior vena cava (IVC), right adrenal 
vein (RAV) and left adrenal vein (LAV) (ratio) 
 
 
 
 
 
 
 
The histological examination documented hypertrophy of the zona reticularis and the 
presence of paracortical micronodules and islands of medullary tissue in the cortex as 
shown in Figure 2.   
 
30 
 
 
Figure 2. Right adrenal gland. A: Hyperplasia reticularis, B: paracortical micronodule; 
C: islands of medullary tissue in the cortex; D: neuronal tissue in the cortex 
 
 
 
 
The follow-up was characterized by the maintenance of good BP values, but persisting 
mild hypokalaemia. Five years later, the patient was hospitalized again for an episode of 
severe tachycardia secondary to hypokalemia. The MR of the abdomen showed a 
further enlargement of the known left adrenal mass with radiological characteristics that 
were not typical for adenoma. The patient was therefore subjected to adrenocortical 
sparing surgery of the left adrenal mass. The histological diagnosis of the excised node 
was adrenal Pheo (positivity for Cromogranin A, sinaptofisina, eNSA, MIB-1, S-100) 
(Figure 3).   
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Figure 3:  Left adrenal gland. A: Vascular gaps and areas of recent hemorrhage; B 
proliferating cells in cord arrangement with compression of the cortex; C:positivity 
for cormagranine A; D: positivity for synaptofisine  
 
 
 
 
Comments: the probability of a  casual coincidence of Pheo and PA in the same patient 
is extremely low. It could, therefore, be that the Pheo was the cause of 
hyperaldosteronism. In this regard, there are two possible ways to explain the 
pathophysiology: A) the production of catecholamines by the Pheo induces the secretion 
of renin (by the stimulation of B2 receptors) and therefore cause secondary 
aldosteronism or B) unknown mediators induced proliferation and hypersecretion of the 
zona glomerulosa resulting in "primary hyperaldosteronism". A whole transcriptome 
analysis of the Pheo tissue of this lady revealed a marked overexpression of UII as 
compared to normal human adrenomedullary tissue. 
(Biochemical and molecular analysis are fully explained in chapter 4.4).  
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4. Can the secretagogue effect of UII on aldosterone be proven in vivo? 
There are many evidences in the literature that support the hypothesis of a cross-talk 
between adrenal medulla and cortex through paracrine mediators;
54
 UII can entail such 
mediators as documented by many authors. The transcripts of UII and its receptor have 
been identified in four APA and seven Pheo
 
and an increased UII-like immunoreactivity 
in one of six Pheo.
64
 Immunostaining for both UII and UT-R was confirmed in in Pheo, 
and for UII in the adrenal medulla and to a lesser extent in the cortex and in 
adrenocortical tumors.
75
 At variance, has been described also a lower UII and UT-R 
expression in Pheo tissue, compared with the normal adrenal tissue.
67 
Therefore, it is not 
only contentious whether UII is differentially expressed between the normal adrenal 
cortex and medulla and between Pheo and APA, but also, more importantly, whether 
UII played any functional role in the adrenal gland.  The finding of UII and UT-R gene 
transcripts in APA and Pheo
64
 suggested the participation of UII in the regulation of 
blood pressure and body fluid homeostasis.  
 
 
4.1 Expression and functional role of UII and its receptor in the adrenal cortex and 
medulla 
Based on the evidences reported above, we have conducted a study in 22 patients 
affected by APA and in 10 patients affected by Pheo aimed to identify the expression of 
UII and UT-R in adrenocortical and adrenomedullary tumors and the functional effects 
of UT-R activation.  
Therefore, molecular techniques were used to quantify precisely the UII and UT-R 
transcripts in APA and Pheo and to pinpoint UII and UT-R related pathways in 
adrenocortical and adrenomedullary tumors. The presence of the UII peptide was 
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investigated by immunoblotting and immunohistochemistry in APA and Pheo. Finally, 
the role of UT-R activation on the adrenocortical expression of aldosterone synthase 
(CYP11B2) and 11_ hydroxylase (CYP11B1) was investigated by means of an in vivo 
UII infusion in rats taking advantage of palosuran. Adrenocortical tissues from 22 
patients with APA and adrenomedullary tissues from 10 patients with Pheo were 
investigated. Histologically normal adrenocortical (NAC) and normal adrenomedullary 
(NAM) tissue obtained from six patients with renal cancer carcinoma undergoing 
unilateral nephrectomy and ipsilateral adrenalectomy and from five patients 
adrenalectomized for non functioning incidentally discovered adrenal mass 
(“incidentaloma”) were studied as controls for the APA and Pheo tissues, respectively. 
The tissues obtained under sterile conditions at surgery were immediately frozen in 
liquid nitrogen and stored at -80 C until they were used as described.
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UII and UT-R mRNAs were measured with a real time RT-PCR; UII and UT-R 
expression in APA and Pheo was calculated relative to porphobilinogen deaminase, 
used as an internal control, and to the control pools of NAC and NAM tissue, used as 
calibrators, for APA and Pheo, respectively. 
Two-color microarray was used to evaluate gene expression;  immunoblot analysis with 
a goat polyclonal antibody was used to investigate the expression of UII and UT-R at 
the protein level.  
To investigate whether the UT-R activation up-regulates the adrenocortical expression 
of the  CYP11B2 and CYP11B1, UII (600 pmol/kg/h)
77 
was infused by osmotic 
minipumps (model2ML2;Alzet, Palo Alto, CA) either alone or on top of the UT-R 
antagonist palosuran (300mg/kg) into normotensive male Sprague Dawley rats (of about 
250 g body weight; n:11). Angiotensin II (Ang II) (700 µg/kg/d) was infused in parallel 
as positive control. After 1-week infusion, the rats were killed, the adrenal gland was 
snap-frozen in isopentane, precooled on dry ice, and then stored under liquid nitrogen 
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until used for immunohistochemistry and gene expression studies. Specific antibodies 
against the rat CYP11B2 or CYP11B1
78 
were used for immunohistochemistry.  
Negative controls were performed by omission of the primary antibody. Sections were 
mounted and examined at 5X magnification, using a Leica DQ optical microscope. The 
immunoreactive area was then calculated with a specific routine developed to detect in 
an operator-independent fashion the brownish staining as percentage of the total adrenal 
cortex. Plasma aldosterone concentrations were measured before and after the UII 
infusion as described.
77
 
The Pheo exhibited higher UII mRNA content than the APA, which showed the lowest 
level among all adrenal tissues examined. It is noteworthy that an opposite expression 
profile of UT-R transcripts across adrenal tumors was detected: the APA showed higher 
mRNA levels than the Pheo and the normal adrenal medulla, suggesting down-
regulation of UT-R when UII expression is enhanced and vice versa. These differences 
suggest a pathophysiological role of UII in the adrenal gland.  
Our studies also showed the UII peptide and the UT-R protein in the normal adrenal 
cortex and in the APA and Pheo tissue. At immunoblotting, besides the expected 43-
kDa band (detected in the human myocardium), we found two additional bands of 60 
and 80 kDa in all adrenal specimens. The disappearance of the 60-kDa band after 
protein deglycosylation indicates the occurrence of a glycosylated form of UT-R in the 
adrenal. The persistence of the 80 kDa after this treatment in APA suggests the presence 
of UT-R dimerization, a finding that deserves further specific research.  
Overall, the UII overexpression in Pheo suggests a major role of UII in the 
pathophysiology of these tumors and particularly in a subset of them that have been 
causally associated with primary aldosteronism.
79-83 
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4.2 Detection and localization of UII in pheocromocitoma tissue and related pathway 
Immunohistochemistry confirmed that UII peptide is synthesized in Pheo and furnished 
novel information on its localization. It showed a specific staining of clusters of Pheo 
cells, sometimes arranged in nests and located in perivascular regions. Moreover, we 
identified 18 sequences with an expression profile similar to that of UT-R, e.g. high in 
APA and low in Pheo. Of these, two pertain to G protein-coupled receptors: the galanin 
receptor 3 (GALR3) and G protein-coupled receptor 153 (GPR153). GALR3 binds 
galanin, a neuropeptide that is synthesized in the adrenal medulla, and Pheo and is 
involved in the regulation of adrenocortical function.
84
 GPR153 encodes an orphan 
receptor not characterized as yet. Of the other sequences, SOX1 and SOX17 entail 
transcription factors belonging to a class of genes known to be expressed during adrenal 
fetal development.
85 
Therefore, these findings emphasize the importance of the 
interactions between the medulla and cortex and implicate these novel mediators in the 
UII-related molecular mechanisms. 
 
 
4.3 Effects of UT-R activation in the rat adrenal cortex 
We explored the functional effect of a chronic UT-R over activation on CYP11B2 or 
CYP11B1 expression with a 1-week infusion of UII in the presence or absence of an 
UT-R antagonist in normotensive rats. This experiment was made possible by the 
development of specific antibodies for these enzymes
78 
and the discovery of the UT-R 
antagonist palosuran.
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UII markedly increased the plasma concentration of aldosterone and the CYP11B2 
expression in the zona glomerulosa; this latter effect was blunted by palosuran, thus 
indicating that it occurred via UT-R activation. Moreover, the UII-induced stimulation 
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of CYP11B2 is likely to be physiologically relevant because the result was more potent 
than that elicited by a high dose of Ang II, the most widely known secretagogue for 
aldosterone. Hence, our data support the hypothesis that UII synthesized in the adrenal 
medulla, and to a larger extent in Pheo, stimulates aldosterone secretion by specifically 
turning on the expression of the CYP11B2 gene in the zona glomerulosa (Figure 4, 5). 
 
 
 
 
 
 
 
 
Figure 4:  Immunohistochemistry shows staining of the rat adrenocortical zona glomerulosa (ZG) with a 
specific antibody for the CYP11B2 
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Figure 5. The histograms show results of 
quantification of the percentage immunostaining 
performed in an operator-independent way. B. The 
ratio of CYP11B2/CYP11B1 immunostaining showed 
a significant (*, P < 0.05) increase only for the group 
infused with UII 
 
 
 
The results of this experiments showed the expression of UII in the normal human 
adrenal gland, in APA and, at a higher level, in Pheo tissue. The opposite trend of 
expression of UT-R between APA and Pheo, along with the differences of genes 
implicated in UII signaling, supports a role of UII in the paracrine interactions between 
the adrenal medulla and cortex. Being relevant for the regulation of adrenal gland 
function and for the pathophysiology of Pheo and APA, these interactions might 
provide a mechanistic explanation for the Pheo that presented clinically as 
aldosteronism.
79-83
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4.4 Biochemical and molecular assessments 
4.4.1 Measurement of UII and UT-R mRNAs 
We measured UII and UT-R mRNAs with a novel real time  reverse transcription (RT)-
polymerase chain reaction (PCR) that utilizes Universal ProbeLibrary Probes (UPL) and 
Universal ProbeLibrary Assay Design by ProbeFinder Software (Roche, Monza, Italy) 
(www.lc480.it) in the LightCycler® 480 Instrument (Roche, Monza, Italy).  To obtain 
RNA free from contaminating DNA, each RNA sample (1 μg) was digested with 
Deoxyribonuclease I Amplification Grade (Invitrogen, Milan, Italy).  After digestion, 
sample quality was re-assessed in an Agilent Bioanalyzer 2100 and re-quantified by 
spectrophotometry. Moreover, primers were chosen to span exon-exon boundaries to 
prevent co-amplification of genomic DNA. One μg of total RNA was reverse-
transcribed with Iscript™ (Bio-Rad, Milan, Italy) in a final volume of 20 μL.  Real-time 
quantitative PCR analysis was carried out on the LightCycler® 480 system by using 
LightCycler® 480 Probes Master (Roche) in 96 multiwell plates according to the 
manufacturer’s instructions.  2μL of each RT reaction was amplified with specific 
primers in a final volume of 20 μL.  Porphobilinogen deaminase (PBGD), an accepted 
housekeeping gene for both adrenocortical and adrenomedullary gland gene expression 
studies, was similarly processed to normalize for RNA quality, quantity, and RT 
efficiency.
86
 
The specificity of the amplicons was verified by sequencing analysis. The PCR products 
were cleaned by GenElute TM PCR Clean-up Kit (Sigma-Aldrich Corp., St. Louis, 
MO), and sequenced at the CRIBI (Centro Ricerca Interdipartimentale Biotecnologie 
Innovative) of our University. Expression of UII, UT-R, and PBGD mRNA was 
quantified with the second derivative maximum method of the Light Cycler Software 
(Roche) by determining the crossing points of samples.  UII and UT-R expression in 
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APA and Pheo was calculated relative to PBGD, used as an internal control, and 
relative to the control pools of normal adrenocortical and medullary tissue, used as 
calibrators, for APA and Pheo, respectively. Quantification of gene expression was 
carried out by comparative Ct (2-ΔΔCt) method.87  Standard curves were generated for 
UII, UT-R and PBGD mRNA by serial dilutions of RT products by spanning five orders 
of magnitude, yielding a PCR efficiency close to one for each reaction. 
 
4.4.2 Measurement of UII and UT-R protein expression 
The expression of UII and UT-R at the protein level was examined by Western blot 
analysis with a goat polyclonal antibody.  Tissues were homogenized separately in 500 
μl lysis buffer (20mM HEPES, 2 mM EGTA, 10 mM β-glycerophosphate, 2 mM 
Na3VO4, 10 μM PMSF, 1 μM leupeptin, 5 μM aprotinin, 1 mM DTT) at 4°C with 
MagNA Lyser Instrument (Roche, Monza, Italy). The lysate was then sonicated with a 
Dounce sonicator, 3 times for 20 s at 4°C and then centrifuged at 10000 rpm for 10 min 
at 4°C.  The protein concentration was determined in the soluble supernatant with 
Lowry’s method, using bovine serum albumin as standard.88   Lysate fraction (60 μg) 
was solubilized in Laemmli buffer and separated by electrophoresis through a 
polyacrylamide gel (15% for UII and 12% for UT-R). The proteins separated on the gel 
were electroblotted onto nitrocellulose membrane (Hybond ECL-Amersham 
Biosciences Europe, Freeburg, Germany) in a blotting buffer containing Tris 48 mmol/l, 
glycine 192 mmol/l, SDS 0.1%, methanol 20% (v/v) per 3 h at 100 V in the cold.  The 
membranes were blocked overnight at 4°C in T-PBS containing PBS, 0.05% (v/v) 
Tween, and 5% bovine serum albumin (BSA) and thereafter. The membranes were 
incubated overnight at 4°C with a primary antibody against UII (1:500 dilution), or UT-
R (1:500), both from Santa Cruz Biotechnology™ (Santa Cruz, CA, USA) and then 
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After washing three times for 15 min the membranes were incubated with the 
horseradish peroxidase conjugated secondary anti-goat antibody (1:5000 Amersham 
Biosciences Europe).  Detection was made with the Enhanced Chemiluminescence 
System (ECL) from Pierce (CELBIO, Milan, Italy). Blots were analyzed by the 
Quantity One Program of VersaDOC 1000 (Bio-Rad, Milan, Italy). 
 
4.4.3 Two-color microarray-based gene expression 
Total RNA was isolated from frozen tissue using RNeasy Mini Kit (Qiagen, Milan, 
Italy).  The integrity of RNA was systematically checked using the lab-on-chip 
technology in an Agilent Bioanalyzer 2100 with the RNA6000 Nano Assay (Agilent 
Technologies, Palo Alto, CA).  Furthermore the purity was determined by 
spectrophotometric readings at 260/280/230 nm. cRNA was synthesized from 500 ng of 
total RNA using the Low RNA Input Linear Amplification Kit and the Two-Color RNA 
Spike-In (Agilent Technologies, Palo Alto, CA).
89 
The Two-Color RNA Spike-In 
consists in a pre-mixed cocktails composed of 10 transcripts that serve as positive 
microarray controls to monitor microarray performance.  The control pool and sample 
were labelled using Cyanine 3 (cy3) and Cyanine 5 (cy5) dyes respectively. In order to 
control for gene specific dye biases and for dye intensity differences, dye swaps and 
biological replicates were included in the experimental design.  
The Labelled/Amplified cRNA was purified using the Qiagen's RNeasy mini spin 
columns and hybridized on an oligomicroarray chip (Whole Human Genome 
Microarray Kit, 1 x 44K, G4112A Agilent Technologies), which contains about 44.000 
60-mer in situ synthesized sequences that comprise the whole human genome. The chip 
was incubated in a rotor oven at 65°C for 17 hours. 
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4.4.4 Chip scanning and data analysis 
The chip was scanned using a dual-laser Microarray Scanner System (Agilent 
Technologies, Palo Alto, CA).  After generating the microarray scan images, tiff images 
were extracted using the Feature Extraction 8.5 software (Agilent Technologies, Palo 
Alto, CA) and data from different microarray experiments were compared by using 
Rosetta Resolver (Rosetta Biosoftware, Seattle, WA). To determine similarities (or 
differences) across arrays and/or sequences cluster analysis was performed. We 
preliminary elected to use a cut-off value of 2-fold to identify over- and under- 
expressed genes. Ontology analysis of sequences differentially expressed was 
performed using the Gene Ontology annotation.
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4.4.5 Immunohistochemistry 
Immunohistochemistry was used to confirm the UII expression at the protein level and 
to visualize its distribution in the pheochromocytoma tissue serial 7-μm slices of 
mounted Pheo were dehydrated three times in xylene and rehydrated in serial dilution of 
ethanol.  A Rabbit Polyclonal IgG for UII was used (Santa Cruz Biotechnology™).  The 
reaction was detected with Sigma Fast 3’,3’- diaminobenzidine, 0.7 mg-tablets (DAB 
Tablets Set, Sigma), as described.
89 
Sections were incubated with hydrogen peroxidase 
(0.5%) for 30 min and with blocking serum solution (BSA 0.2% triton 0,2% NGS 1:50 
in PBS) for 20 min.  After incubation with primary antibody to UII Rabbit Polyclonal 
IgG (1:50) at 4°C overnight, the sections were incubated at room temperature for 1 h 
with a secondary Biotin SP-conjugated IgG Mouse anti Rabbit (Jackson 
ImmunoResarch Laboratories, Inc, West Grove, PA, USA) (1:500) and then with 
Peroxidase-conjugated Streptavidin (Jackson ImmunoResarch Laboratories™) at room 
temperature for 30 min (1:250).  The reaction was developed for 5 min with DAB 
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Tablets and stopped with water.  Negative controls were performed by omission of the 
primary antibody and pre-incubation of the primary antibody with UII. 
 
4.4.6 UT-R activation in rats  
After 1 week infusion  (UII (600 pmol/Kg/h), either alone or on top of the UT-R 
antagonist palosuran (300 mg/Kg) by osmotic Alzet mini-pumps and Ang II (700 
pmol/Kg/h) in parallel as positive control 
91
)   the rats were sacrificed, the adrenal gland 
was snap frozen in isopentane pre-cooled on dry ice and then stored under liquid 
nitrogen until used for the immunohistochemistry (IHC) and the gene expression 
experiments. 
For IHC we used a specific antibody against the rat aldosterone synthase (CYP11B2) or 
11β hydroxylase (CYP11B1).92 
Tissue sections were processed as described for human Pheo.  Binding was detected 
with primary antibody diluted 1:50 in BSS was performed overnight at 4°C. After 
washing sections were incubated with secondary antibody (Biotin-SP-Conjugated 
AffiniPure Goat Anti Mouse IgG+IgM (H+L), Jackson Immuno Research) diluted 
1:500 in BSS for 1 h at room temperature. They were rinsed again and subsequently 
incubated for 30 min at room temperature with the Horseradish Peroxidase conjugated 
streptavidin (Peroxidase conjugated Streptavidin, Jackson Immuno Research) diluted 
1:250 in BSS. The reaction was developed for 5 min with DAB Tablets and stopped 
with water.  Negative controls were performed by omission of the primary antibody.  
Sections were mounted and examined at 5x magnification, using Leica DQ optical 
microscopy. The immunoreactive area was then calculated with a specific routine that 
was developed to detect the brownish staining in an operator-independent fashion as 
percent of the total adrenal cortex. 
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5. Does UII determine transient increase of blood pressure by stimulating    
aldosterone secretion? 
5.1 Analogies between blood pressure trend in chronic infusion of UII and chronic 
infusion of aldosterone 
What emerged  in our studies regarding  the expression of UII and its receptor (UT-R) 
in adrenal tumors suggests a key role UII as regulator of adrenal secretion and on 
development of cortical tumors. This strengthened the hypothesis that the mechanism of 
action of UII is closely connected with RAAS. 
We  have investigate the effects on BP  in rats chronically infused with UII. UII was 
infused via osmotic Alzet minipumps at a dose of 600 µmol/Kg/h. BP was continuously 
monitored by an invasive telemetric system through intra-abdominal aortic blood probes 
as detailed described on chapter 5.2.2. With this system it was possible to have a 
continuous and not intermittent monitoring of BP obtaining a high quantity of values 
without losing any, albeit transient, BP variation. 
Figure 6  shows one typical plot that we obtained regarding the BP trend since the 
beginning of UII infusion.  
 
Figure 6. Blood pressure trend in chronic infusion of UII in rats 
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This  BP plot was very interesting in our opinion since it shows a rise in BP that was 
detected approximately 24 hours after the beginning of administration of UII followed 
by a subsequent adaptation to the baseline BP values. This was in contrast with the 
other “in vivo” studies since for the first time led to suspect a even transient systemic 
pressor effect of UII.  
We observed that the BP trend in rats chronically infused with UII looks similar to the 
BP trend in chronic infusion of aldosterone
93 
(Figure 7) and this further supports the 
hypothesis of interaction between UII and RAAS or even that UII acts through 
production of aldosterone as well as assess its hypertensive activity, its effect of cardiac 
hypertrophy and fibrosis and its role in regulating the growth of adrenocortical cells in 
rats.  
 
 
Figure 7. The figure highlights the analogy between the development pressure in the chronic infusion of aldosterone 
(A) as assess by Grim CE 93 and in chronic infusion of Urotensin II (B) Both trends are characterized by an initial 
hypertensive peak followed by a phase of adaptation returning to the baseline blood pressure values. This trend in the 
case of chronic infusion of aldosterone is attributable to the renal “escape phenomenon”. 
 
The BP curve in both chronic infusion of aldosterone and UII tends to settle on the 
baseline values after an initial increase of BP, and this in cases of hyperaldosteronism is 
attributed to the onset of the mechanisms that regulate the renal phenomenon of 
"escape": after the initial hypertensive state secondary to the reabsorption of sodium and 
water, the subsequent natriuresis induces a reduction in volume resulting in return to 
45 
 
normal blood pressure values. Thus,  if our hypothesis is true, we expect that 
eliminating the effect of escape phenomenon the pressure curve in the chronic infusion 
of UII will present the disappearance of the adjustment of BP after the initial pressor 
effect. 
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5.2 Evaluation of interactions between UII and the renin-angiotensin aldosterone 
system by chronic infusion of UII in rats 
The results just shoen along with those from studies on adrenal tumors, reinforced the 
hypothesis  that UII is a putative mediator of the effects of the adrenal medulla on the 
adrenocortical zona glomerulosa, playing a key role in regulating the growth of 
adrenocortical cells. Moreover, this pathophysiological link might account for the 
reported causal relationship between pheochromocytoma and primary aldosteronism.
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The contention that UII  acts through the RAAS or that UII might increase via unknown 
mechanisms the production of aldosterone has been also supported by our previous  
evidences in which it was shown that the BP trend  in rats chronically infused with UII 
was similar to that of chronic infusion of aldosterone (figure 7B).   
Based on these  considerations we aimed to investigate among the mechanism of action 
of UII evaluating any possible change in BP trend once counteracted the mechanisms 
that affect the physiological development of blood volume and pressure in states of 
hyperaldosteronism.  
In fact if in states of hyperaldosteronism (such as chronic infusion of aldosterone) is 
observed a progressive increase in BP related to the reabsorption of sodium and water 
followed by a gradual return to the baseline pressure values  due to the mechanisms of 
renal escape (figure 7A,B), assuming an interaction between UII and RAAS, we expect 
a change in blood pressure trend in chronic infusion of UII by removing the renal 
phenomenon of escape. We tested this hypothesis on four groups of rats, each one 
consisting in chronic infusion of UII in association to a concomitant system to 
antagonize the RAAS and the “escape” assessments. 
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5.2.1 Study design 
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA), 15 weeks of 
age (main weight 427g ± 59.8) were divided into four  groups of twelve animals each 
consisting in 6 cases and 6 controls; each case was treated by infusion of UII 
(600pmol/kg/h) each control by infusion of vehicle. In each group was set up a system 
aimed to antagonize the renal adaptation to the hyperaldosteronism (escape 
phenomenon) or to abolish the aldosterone production. The effect of renal escape was 
counteract through unilateral nephrectomy, thus reducing by 50% the natriuretic renal 
capacity in association with the administration of diet high in sodium to counteract the 
effect of the natriuresis. Administration of spironolactone was also  used to counteract 
the natriuresis, while bilateral adrenalectomy was performed in order to abolish the 
aldosterone production. Four groups of rats were identified: 
 - Group 1 unilateral nephrectomy (left kidney) and very high sodium diet (4% NaCl) 
- Group 2 unilateral nephrectomy (left kidney) and high sodium diet (2% NaCl)  
- Group 3 bilateral adrenalectomy  
- Group 4 concomitant administration of spironolactone 
Originally it was thought that only a group with unilateral nephrectomy and hypersodic 
diet (NaCl 4%) could allow to solve the question. However, considering the high 
mortality of the rats probably secondary to the high salt concentration and the 
consequent dehydration we found it necessary to prepare another group to be submitted 
to a milder hypersodic diet (2% NaCl, group 2). The hypersodic intake was in fact 
achieved by giving a normal sodium diet and adding salt to drinking water prepared as 
distilled water plus NaCl. With 4% NaCl the rats did not dink enough and therefore died 
of dehydration. The lower  saline concentration (2% NaCl in group 2) was better 
tolerated. BP was continuously monitored through intra-aortic blood probe via DSI 
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telemetry system (as described in details in chapter 5.2.2). At the time of intra-
abdominal probe implantation was also performed left nefrectomy or bilateral 
adrenalectomy according to the different group of treatment. UII (600 pmol/Kg/h) and 
spironolactone (20mg/Kg/die), were administered subcutaneously by osmotic mini-
pumps (model 2ML1, 7-day infusion, Alzet, Palo Alto, CA) starting seven days after 
surgery; a skin incision at the interscapular region was performed on the animals under 
gas general anesthesia and the  minipump was there implanted within the subcutaneous 
tissue. Alzet minipumps with saline solutions were used for controls. Plasma 
aldosterone, sodium and potassium were measured in blood samples collected from the 
tail vein at the end of the first week and the end of the experiment. Urinary collection 
and sampling were obtained by metabolic cages (blood pressure mesurements were not 
obtained in those rats).  On day 14 the rats were anesthetized, weighed and killed. 
Hearts, adrenals and kidneys were removed, weighted and collected for histology. Left 
ventricle-to body weight (LV mass index) was calculated. Figure 8 resumes the study 
design. 
 
Figure 8. Study design 
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The protocol followed current guidelines (NIH publication no. 93-23, revised 1985) and 
was approved by the Institutional Animal Care and Use Committee. 
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5.2.2 Telemetry system for blood pressure monitoring 
The Dataquest IV telemetry system (Data Sciences International, Arden Hills, MN) was 
used for the direct measurement of systolic, diastolic and mean blood pressure (MBP), 
through intra-abdominal aortic BP probes (Figure 9). The implantation of the probes 
was obtained in general gas anesthesia (isofurane) through  a midline laparotomy and 
isolation of the abdominal aorta. After its clamping with a silk thread suspension, the 
aorta was cannulated above the carrefour with a 21G needle and then running through to 
introduce the tip of the probe inside the aorta. The small entry hole was sealed with 3M 
vetbond tissue adhesive (DSI) and a patch of cellulose (DSI). The probe body was fixed 
to the abdominal wall within the abdominal cavity by means of suture thread with 
flexidene.  The rats were then placed individually in their cages, and were unrestrained 
and untethered. Systolic and diastolic blood pressure  were monitored continuously at a 
sampling rate of 5 minutes during 24 h. After exclusion of outliers the mean daytime 
(rest time: 7 AM to 6:59 PM) and night-time values were calculated. 
 
 
 
Figure 9. After the cannulation of abdominal aorta and the storage of the probe in the 
abdominal cavity the rats were placed on their cages and a telemetry system detected 
blood pressure through radio frequencies and ploted the values. 
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5.3.2 Blood Pressure trends and systemic response 
Group 1 ( UII + unilateral nephrectomy and diet added of 4% NaCl) 
In this group the escape phenomenon was contrasted by a 50% reduction in renal 
function (unilateral (left) nephrectomy) in combination with hypersodic diet (water 
added of 4% NaCl).  In this first group the rats showed bad general conditions from  the 
beginning of the observation, the 4% saline solution administered proved to be poorly 
tolerated by the animals and the amount of water consumed per day was extremely 
little. which suggested that this amount of sodium in water was not appropriate and 
decreased markedly water intake. This group was characterized by high mortality (4 
rats, 33%): one rat died because of intraoperative hemorrhagic shock during  the 
implantation of the BP probe; 3 rats died during the observation, one of them had  
paraplegia of posterior extremities and the remained 2 died for unknown causes. Those 
that completed the 15 days treatment (8 rats (67%), 5 cases and 3 controls) showed very 
poor general conditions characterized by extremely low reactivity and very clear clinical 
signs of dehydration.  
Mean baseline weight (measured at the day 7, corresponding to the beginning of UII 
infusion) was 410g while at the time of sacrifice it was reduced at 310g with a mean 
weight loss of 91g; both cases and controls showed weight loss at the time of sacrifice 
(mean weight loss for cases: -80g, mean weight loss for controls: -110g). Table 4 
resumes weights among groups. 
BP measurement was obtained in a total of 4 rats, 3 cases and 1 control.  In cases treated 
with UII mean weekly BP during the day (MBP-day) was 115mmHg, and mean weekly 
BP during the night (MBP night) was 112mmHg. The only control treated showed 
surprisingly higher BP values than the cases (MBP-day: 140mmHg, MBP-night: 138 
mmHg). Table 5 resume BP values among groups.  
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Despite the discrepancy relative to the average pressure values among cases and 
controls the time course of the pressure in the cases was exciting considering the 
tendency towards progressive increase and the disappearance of the chronic 
phenomenon of adaptation towards the initial values, as showed in Figure 10.  
 
 
Figure 10. Blood pressure trend in a case  treated by UII infusion + left nephrectomy and 4% 
NaCl diet (group 1). Red line point the beginning of UII infusion. Blood pressure values tend to 
increase over the time  with the disappearance of the chronic adaptation to the initial level seen in 
it the UII infusion alone. 
 
 
BP trend in the cases was characterized by a  progressively increase of values with the 
disappearance of the initial 24h peak and the chronic adaptation to baseline values 
observed in the infusion of UII alone (figure 10). Thus, this result appeared to be 
consistent with the hypothesis of a possible interaction between aldosterone and UII 
seemed to be confirmed: the abolition of the escape effect led to a continuous chronic 
increase in blood pressure. However the comparison with the only control survived was 
disappointing since the mean blood pressure  values were higher than cases even in 
absence of infusion of UII . Probably the baseline values in that rat was higher than the 
controls, or its renal function was still impaired and not excludible any  problem 
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regarding the transducer. Despite the average higher pressure values the tendency to 
gradual pressure increase over time in this rat was less evident. 
LV mean weight in group 1 was 0.73g, (0.72g for cases and 0.75 for controls) while the 
ratio LV over body weight (LV/BW) ratio was 2.3 for cases and 2.6 for controls. 
Table 6 shows the left ventricle weights  comparing the groups.  
 
Group 2. ( UII + unilateral nephrectomy and diet added of 2% NaCl) 
In view of the results obtained in group 1 (especially with regard to mortality) it was 
decided to change the protocol and to introduce group 2 characterized  by unilateral left 
nephrectomy in addition to mild hypersodic diet, giving water containing 1% NaCl in 
the first week after nephrectomy and implantation of the probe, and 2% in the last seven 
days. 
The general conditions of rats in this group were globally better than those of rats in 
Group 1. The lower concentration of sodium chloride (2%) allowed the rats to drink a 
daily amount of water sufficient to avoid the heavy dehydration that characterized  
group 1. The mortality was 17%  (2 rats) one case because of intra-operative 
complications during probe implantation, one during the treatment probably because of 
uroperitoneum. Final general conditions of rats were at the end the observation globally 
good, and this was confirmed also by the weight and blood pressure values analysis. 
Mean baseline body weight of group 2 was 454g, and the final was 395g (with a total 
decrease approximately of 60g); the weight decrease was more evident in cases ( less 
80g from day 7 to day 14) but was globally lower than group 1. (Table 4)  
BP monitoring was obtained in 3 cases and 3 controls with a MBP-day of 132mmHg 
and MBP-night of 124 mmHg for cases and respectively of 122 mmHg and 117 for 
controls (Table 5). The BP plots in cases receiving UII were very satisfying since the 
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BP trend was confirmed to be  progressively increasing during the UII infusion, with the 
disappearance of the  chronic adaptation to the baseline values. (Figure 11) 
This confirmed that the infusion of UII in association with counteracting the 
phenomenon of escape (by unilateral left nephrectomy and high sodium diet) causes a 
progressive increase in BP with the disappearance of the phenomenon of chronic 
regression toward baseline values. 
Also in this group controls documented a BP trend less homogeneous albeit with high 
mean values despite the absence of treatment and probably influenced by the increased 
concentration of NaCl (2%) in the diet. 
Mean LV weight in this group was  0.76g (0.85g in cases, 0.65 in controls) and LV/BW 
ratio was respectively 2.03 and 2.01. (Table 6) 
The survival rate and the general conditions of the rats completing the observation were 
significantly better than the  group 1.  
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Figure 11. Blood pressure trend in two cases (A, B) and one control (C) of group 2  (left 
nephrectomy and  2% NaCl diet). The red line shows the beginning of UII infusion. In A 
and B the plots show a trend of continuous increasing of blood pressure values with the 
disappearance of the chronic adaptation to baseline values seen in UII infusion alone. The 
plot C (vehicle) documents a less regular pattern of blood pressure, although higher values 
than those of baseline,  much less prone to the progressive increase 
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Group 3 (UII + bilateral adrenalectomy) 
This group was planned to investigate among the effects of UII in absence of 
aldosterone production. Unfortunately, this group had the worst outcome. The mortality 
was extremely high (rising 83%, 10 rats on 12) and the majority of animals died two 
dyes after the adrenalectomy. Only two cases survived until the end of the experiment. 
No BP analysis was obtained in these two cases. Their final general condition were very 
poor showing an  extremely reduced reactivity.  
The mean body weight showed a little decrease (from 399g to 385g) and the LV mean 
weight was 0.74g with a LV/BW of 1.93. 
 
 
Group 4 (UII + spironolactone) 
In this group, the escape phenomenon was antagonized by co-administration of 
spironolactone at a dose of 20 mg/kg/die at the same time of UII via Alzet minipump. 
The mortality in this group was 25% (3 over 12 rats enrolled) with a total of 6 cases and 
3 controls survived till the end of the experiment. 
General conditions of rats, in term of reactivity and blood pressure values, were good 
during all the days of observation, and this was the only group in which we could 
document a global increase of the final body weight (plus 10g from the baseline), due to 
an increase of about 30g in cases against a similar weight loss of controls (Table 4). 
BP  monitoring was obtained in 4 cases showing a global maintenance of baseline 
values, with a MBP-day of 100mmHg and MBP-night of 100mmg. The plots showed  
the absence of the chronic increase in blood pressure as observed in the previous groups 
while an initial hypertensive peak (similar to the one observed in the infusion of UII 
alone) was detectable in all the four plots obtained. (Figure 12) 
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LV mean weight was 0.86g (0.86g in cases and 0.74 in controls, with a LV/BW 
respectively of 1.78 and 2.24). 
The general conditions of the animals at the end of observation were good and the 
performance pressure proved to be stable, without the propensity to increase over time 
and maintaining that initial hypertensive peak observed at approximately 24 hours after 
administration of single continuous UII (figure 12). 
 
 
 
Figure 12. Blood pressure trend in concomitant infusion of UII and spironolactone (group 4). The 
plots denote a global maintenance of baseline values over the time, without tending to increase. It 
is evident an initial hypertensive peak as observed in the UII infusion alone 
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Groups  Global Cases Controls 
Baseline 
weight 
Final weight  
  
Baseline 
weight 
Final weight  Baseline 
weight 
Baseline 
weight 
1 401 310 (-91) 399 321 (-80) 403 291 (-110) 
2 454 395 (-60) 501 421 (-80) 407 365 (-40) 
3 399 385 (-16) 399 385 (-15)   
4 435 445 (+10) 446 476 (+30) 414 385 (-30) 
 
Table 4.  Mean body weight (expressed in grams) for each group and for cases and controls. In brackets the main variation among 
the beginning and the end of  treatment.  
 
 
 
 
 
 Global Cases Controls 
 
Mean 
(mmHg) 
Std. Dev Mean 
(mmHg) 
Std. Dev Mean 
(mmHg) 
 
Std. Dev 
MBP-Day Group 1 
 
121 11.1 115 2.32 140 1.9 
Group 2 
 
127 6.92 132 2.7 122 6.07 
Group 4 
 
100 6.96 100 6.96 - - 
MBP-Night Group 1 
 
119 11.67 112 3.07 138 1.76 
Group 2 
 
121 5.69 124 2.97 117 5.88 
Group 4 
 
100 6.31 100 6.31 - - 
 
Table 5. Mean blood pressure during day (MBP-Day) and night (MBP-Night) among groups. 
 
 
 
 
 
 
Groups LV LV / BW 
 Global Cases Controls Global Cases Controls 
1.  (UII + NaCl 4%) .73 .72 .75 2.4 2.3 2.67 
2.  (UII + NaCl 2%) .76 .85 .65 2.03 2.03 2.01 
3.  (Adrenalectomy) .74 .74 - 1.93 1.93 - 
4.  (UII + 
spironolactone) 
.86 .86 .74 1.95 1.78 2.24 
 
Table 6. Left ventricle (LV) mean weight expressed in grams for each group and for cases and controls. Left ventricle over 
body weight (LV/BW) expressed in absolute value for each group and for cases and controls. 
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5.2.4 Considerations on BP trends and statistical analysis 
On a first analysis of the graphs is observed a trend of progressive increase of the MBP  
pressure in rats of groups 1 and 2, while in group 4, the pressure seems to adapt 
substantially to the values of baseline. The pressure peak that was observed within 24 
hours from the beginning  of  single UII infusion seems less evident in groups 1 and 2 
than in group 4. 
Statistical analysis of BP has confirmed these observations, documenting the average 
values pressure (analyzed for day and night) significantly higher for groups 1 and 2 
compared to group 4. (Table 5) 
We made a statistical analysis of covariance normalizing the results for the BP values of 
the baseline and of the day of implantations that has confirmed the progressive increase 
in BP for groups 1 and 2 than in group 4. (Figure 13) 
Among the unexpected data is the fact that have been obtained  higher BP values have 
in rats belonging to the group 2 (2% NaCl diet) compared to rats belonging to the group 
1 (4% NaCl data). It is likely  that the 4%NaCl diet has played an important role in the 
dehydration of rats thus resulting in a volume depletion and hypotension. 
The effect of spironolactone in influencing the development of BP  in rats of group 4 
was evident, however, in group 4 remains still evident the peak pressure to 24 hours 
after the start of administration of UII. 
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Figure 13. Covariate analysis of blod pressure trends in cases of group1, 2 and 4 normalized for baseline and 
implantation day values. 
 
 
 
As regards the LV hypertrophy Table 6 shows that both in group 2 and in group 4 cases 
have a LV weight greater than the controls. In group 1 controls appear to have greater 
cardiac hypertrophy, probably secondary to the fact that controls in group 1 had higher 
blood pressure values. Looking at LV/BW ratio it was evident that the group with 
higher values was group 1: however, this can be interpreted as a "false hypertrophy" in 
consideration of the fact that these rats at the end of the experiment had a significant 
decrease in weight as excessively dehydrated  (data confirmed also by controls that have 
a normalized ratio even higher despite the absence of UII). 
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5.2.5 Limitations of the study 
Despite the results obtained regarding in particular BP trends this study still maintains 
many limitations. The main weakness of this study concerns the control groups, which 
are too few and sometimes inappropriate. This affected especially group  1 where  the 
only control plotted probably had baseline characteristics so peculiar to confuse the 
results obtained. Despite the idea of suppressing the endogenous production of 
aldosterone by the bilateral adrenalectomy in group 3 seemed initially good we should 
have considered to supply the animals with exogenous corticosteroids (ex. pellets in 
continuous release of DOC) in addition to a mild hypersodic diet  in order to avoid the 
acute hypoadrenalism that probably led to death the majority of the rats belonging to 
group 3. Moreover, it will be necessary to perform a further control group characterized 
by nephrectomy plus hypersodic diet and concomitant administration of both UII and 
spironolactone in order to prove the aldosterone mediated role in the pressure action of 
UII. 
Notwithstanding these limitations this study documented for the first time the in-vivo 
pressure effect of UII. The fact that the trend of BP changes in situation of abolition of 
the “escape phenomenon” suggests that UII acts through the RAAS or at least that there 
is close communication between UII and RAAS.  
These study, in combination with the evidences regarding the role of UII in the 
development of cortical tumors, has taken a step forward in identifying the mechanism 
of action of UII in supporting to the hypothesis of a possible close communication 
between medulla and adrenal cortex and a possible action of UII mediated by 
aldosterone. 
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6. Transgenic rat overexpressing UII 
To further prove the concept of a paracrine interaction between the adrenal medulla and 
the zona glomerulosa involving UII, after two years of  unsuccessful attempts , in 
collaboration with Prof. M. Bader at MDC (Max Delbrück Center for Molecular 
Medicine) in Berlin we finally generated a transgenic rat overexpressing UII in adrenal 
medulla. This animal model will provide us more information about the physiological 
role and mechanism of action of UII, particularly, we believe it will certainly clarify the 
real existence of a paracrine effect of UII within the adrenal gland and its close 
correlation with aldosterone secretion. 
To obtain the specific expression of UII in the adrenal medulla, we generated a knock-in 
rat model with UII gene under the control of the promoter of phenylethanolamine N-
Methyltransferase (PNMT), a gene held to be exclusively expressed in the adrenal 
medulla. The tissue-specific UII knock-in rat was obtained by the conventional 
transgenic method in which a DNA fragment containing the PNMT promoter linked to 
the UII coding sequence is microinjected into the pronuclei of fertilized rat oocytes. 
After the transfer the oocytes into foster mothers, the progeny expressing  the UII 
coding sequence in the desired pattern was identified.  
Currently we are going to characterize the first offspring of UII knock-in rat. The 
expression of UII gene will be assessed in adrenal medulla of the UII knock-in rat using 
quantitative real time PCR (qRT-PCR). To verify that UII is exclusively overexpressed 
in adrenal medulla immunohistochemistry analysis will be performed on adrenal gland 
sections.  
After the assessment that the UII knock-in rat overexpress UII specifically in adrenal 
medulla, several experiments will be carry on in order to deepen the investigations 
about the effects of UII on blood pressure and aldosterone secretion.  
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We intend to use again the telemetry system for monitoring blood pressure in our 
animal model and real time PCR to investigate on the expression of steroidogenic 
enzymes in the adrenal gland. 
We are confident that we will solidly confirm what we already demonstrated so far. 
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